Søren E. Degn is an Associate Professor at the Department of Biomedicine, Aarhus University, a Lundbeckfonden Fellow and a Carlsberg Foundation Distinguished Fellow.
Søren completed his BSc (2004) and MSc (2007) in Molecular Biology at Aarhus University. During his MSc, he spent 1 year at the Departments of Biochemistry and Immunology at the University of Toronto, Canada where he worked with Professor David E. Isenman. Søren then joined the laboratory of Professors Jens Chr. Jensenius and Steffen Thiel in Aarhus, where he completed his PhD in Immunology (2010), on the topic of the lectin pathway of complement. His thesis work included the discovery of a novel regulatory component of this pathway, the protein MAp44 (Degn et al., Journal of Immunology, 2009). In the course of his PhD studies, Søren also worked for a year in the laboratory of Professor Michael C. Carroll at the Immune Disease Institute, Harvard Medical School, where he contributed to elucidating how influenza viral antigen is transported and presented in the draining lymph node in a vaccination setting (Gonzalez et al., Nature Immunology, 2010).
Following award of his PhD degree, Søren continued his work on the lectin pathway of complement as a postdoctoral fellow (2011-2013) with Professors Jens Chr. Jensenius and Steffen Thiel. In a series of papers (Degn et al., Journal of Immunology, 2012; Degn et al., Journal of Immunology, 2013; Degn et al., PNAS, 2014), Søren presented a novel theory for the activation mechanism of the lectin pathway of complement.
In 2013, he returned to the laboratory of Professor Michael C. Carroll, now at the Program in Cellular and Molecular Medicine (PCMM) at Boston Children’s Hospital and Harvard Medical School. During his Marie Curie Fellowship at the PCMM, Søren built his expertise within lymphocyte biology using in vivo models and two-photon microscopy, forming the basis of his return to Aarhus University as a Group Leader and Assistant Professor in 2017. His group explores basic functions of lymphocytes in health and disease using a breadth of techniques. For more info, please refer to http://degnlab.au.dk